Sid Sijbrandij

I've also started, in the meantime, six companies to scale treatments for other people.

Treatments that I've done, but also treatments I've not done, but just technologies we came across that we thought are underinvested in.

Yeah, for sure.

I might have been one of the first people to do single cell sequencing as an individual patient outside of the context of a trial.

It's kind of a strange name because

you're not sequencing a single cell, you're sequencing thousands of cells, but you're able to see the genetic markup of each cell, and you're able to see what the tumor is looking like, like which cells are in there, how do they behave, and what's their genetic markup.

It's an incredible, powerful technology.

We compared that to an atlas of kind of what bone marrow should look like.

And we zoomed in.

We were able to kind of zoom in on the cancer cells.

And one thing we noticed is that they had a lot of fibroblast.

Fibroblast is kind of scar tissue.

And we were aware of a treatment in Germany, an experimental treatment that has an FAP binder that binds to fibroblast.

And then on the other side, you put a radioactive element, lutetium or actinium.

And I did two treatments there with incredibly good results.

First of all, no side effects.

I couldn't detect any.

And we saw 60% necrosis.

And 20% shrinkage, which considering it was only two treatments, that was a great result.

And my cancer is in my back near my spinal cord.